Combination of a Novel Fusion Protein CD3εζ28 and Bispecific T Cell Engager Enhances the Persistance and Anti-Cancer Effects of T Cells

SIMPLE SUMMARY: Bi-specific T cell engager (BiTE) has shown promising therapeutic potential in preclinical and clinical studies. However, T cells cannot be sufficiently activated by BiTE, most likely due to lacking co-stimulatory signal. We, therefore, designed a chimeric fusion protein, named as CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Feng, Gao, Yang, Wu, Yan, Dai, Anran, Wang, Xiaoyan, Zhang, Xiangzhi, Liu, Guodong, Xu, Qinggang, Chen, Dongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563022/
https://www.ncbi.nlm.nih.gov/pubmed/36230871
http://dx.doi.org/10.3390/cancers14194947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563022/
https://www.ncbi.nlm.nih.gov/pubmed/36230871
http://dx.doi.org/10.3390/cancers14194947

Ejemplares similares